Profile data is unavailable for this security.
About the company
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases, and rare diseases. It helps in accelerating and improving the traditional drug development process through its VelociSuite technologies. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; REGEN-COV; Kevzara (sarilumab) Injection, and others. The Company’s solid tumor and other oncology and autoimmune cell therapy programs include the bbT369 program in B-NHL, SC-DARIC33 in AML, MUC16 in ovarian cancer, MAGE-A4, autoimmune, and several unnamed targets.
- Revenue in USD (TTM)13.12bn
- Net income in USD3.95bn
- Incorporated1988
- Employees13.45k
- LocationRegeneron Pharmaceuticals Inc777 Old Saw Mill River RoadTARRYTOWN 10591United StatesUSA
- Phone+1 (781) 370-5000
- Websitehttps://www.regeneron.com/
Mergers & acquisitions
| Acquired company | REGN:NSQ since announced | Transaction value |
|---|---|---|
| Decibel Therapeutics Inc | 16.18% | 148.48m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zoetis Inc | 8.54bn | 2.34bn | 68.34bn | 14.10k | 29.50 | 13.72 | 24.14 | 8.00 | 5.07 | 5.07 | 18.48 | 10.90 | 0.585 | 1.03 | 6.78 | 605,957.40 | 16.02 | 14.47 | 19.37 | 17.18 | 70.47 | 69.80 | 27.39 | 25.77 | 2.00 | 17.15 | 0.5682 | 26.89 | 5.74 | 7.96 | 10.88 | 11.13 | 16.71 | 24.37 |
| Gilead Sciences, Inc. | 27.12bn | 5.66bn | 83.58bn | 18.00k | 14.88 | 3.66 | 10.06 | 3.08 | 4.50 | 4.50 | 21.56 | 18.33 | 0.4328 | 3.95 | 5.75 | 1,506,445.00 | 8.96 | 6.74 | 10.91 | 8.12 | 76.04 | 78.64 | 20.69 | 16.95 | 1.27 | 8.78 | 0.5234 | 81.22 | -0.6048 | 4.15 | 23.37 | 0.7436 | -8.74 | 5.64 |
| Bristol-Myers Squibb Co | 45.01bn | 8.03bn | 99.29bn | 34.10k | 12.70 | 3.36 | 5.58 | 2.21 | 3.86 | 3.86 | 21.66 | 14.56 | 0.4689 | 4.24 | 5.01 | 1,319,824.00 | 8.38 | 3.05 | 10.89 | 3.76 | 76.44 | 76.13 | 17.86 | 7.69 | 1.31 | 12.39 | 0.5743 | 133.63 | -2.50 | 14.81 | 26.84 | 10.03 | 4.92 | 7.34 |
| Regeneron Pharmaceuticals Inc | 13.12bn | 3.95bn | 99.59bn | 13.45k | 26.10 | 3.82 | 22.77 | 7.59 | 34.76 | 34.76 | 115.32 | 237.41 | 0.4211 | 0.7289 | 2.39 | 975,256.50 | 12.69 | 20.18 | 14.19 | 23.22 | 86.16 | 86.63 | 30.14 | 38.11 | 4.94 | -- | 0.0943 | -- | 7.76 | 14.34 | -8.87 | 10.72 | 19.32 | -- |
| Vertex Pharmaceuticals Incorporated | 9.87bn | 3.62bn | 104.65bn | 5.40k | 29.15 | 5.94 | 27.53 | 10.60 | 13.89 | 13.89 | 37.88 | 68.22 | 0.4828 | 2.10 | 6.57 | 1,827,630.00 | 17.71 | 19.92 | 20.93 | 23.64 | 87.21 | 87.67 | 36.68 | 35.85 | 3.78 | -- | 0.021 | 0.00 | 10.51 | 26.49 | 8.96 | 46.50 | 22.02 | -- |
| Amgen Inc | 28.19bn | 6.72bn | 146.60bn | 26.70k | 21.90 | 23.50 | 13.59 | 5.20 | 12.49 | 12.49 | 52.42 | 11.64 | 0.3474 | 1.16 | 4.39 | 1,055,805.00 | 8.28 | 10.36 | 10.48 | 13.06 | 70.16 | 75.41 | 23.83 | 26.51 | 1.13 | 3.15 | 0.912 | 59.54 | 7.09 | 3.49 | 2.52 | -4.36 | 8.54 | 10.04 |
| Pfizer Inc | 58.50bn | 2.13bn | 149.04bn | 88.00k | 73.26 | 1.67 | 17.61 | 2.55 | 0.3593 | 0.3566 | 10.29 | 15.77 | 0.2761 | 1.88 | 5.29 | 664,738.60 | 1.03 | 8.20 | 1.30 | 10.40 | 69.24 | 69.34 | 3.71 | 22.68 | 0.6935 | -- | 0.446 | 60.11 | -41.70 | 7.46 | -93.20 | -7.94 | 12.21 | 3.82 |
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 9.67m | 8.95% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 8.39m | 7.77% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 5.66m | 5.25% |
| JPMorgan Investment Management, Inc.as of 31 Dec 2023 | 5.52m | 5.11% |
| Capital Research & Management Co. (World Investors)as of 31 Dec 2023 | 5.13m | 4.75% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 4.90m | 4.54% |
| Capital Research & Management Co. (International Investors)as of 31 Dec 2023 | 2.92m | 2.70% |
| Dodge & Coxas of 31 Dec 2023 | 2.37m | 2.19% |
| Geode Capital Management LLCas of 31 Dec 2023 | 2.35m | 2.18% |
| Loomis, Sayles & Co. LPas of 31 Dec 2023 | 1.22m | 1.13% |
